Dogwood Therapeutics, Inc. - 8-K Filing

Dogwood Therapeutics reports Q3 2026 net loss of $4.9 million and announces $5 million private placement to fund Phase 3 activities. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $DWTX

Read the full article at SEC EDGAR

More Regulatory news